Gut mycobiome in metabolic diseases: Mechanisms and clinical implication

Xingyu Zhou; Xiang Zhang; Jun Yu

doi:10.1016/j.bj.2023.100625

Gut mycobiome in metabolic diseases: Mechanisms and clinical implication

Biomed J. 2023 Jun 25:100625. doi: 10.1016/j.bj.2023.100625. Online ahead of print.

Authors

Xingyu Zhou¹, Xiang Zhang¹, Jun Yu²

Affiliations

¹ Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
² Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address: junyu@cuhk.edu.hk.

PMID: 37364760
DOI: 10.1016/j.bj.2023.100625

Abstract

Obesity, type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are three common metabolic diseases with high prevalence worldwide. Emerging evidence suggests that gut dysbiosis may influence the development of metabolic diseases, in which gut fungal microbiome (mycobiome) is actively involved. In this review, we summarize the studies exploring the composition changes of gut mycobiome in metabolic diseases and mechanisms by which fungi affect the development of metabolic diseases. The current mycobiome-based therapies, including probiotic fungi, fungal products, anti-fungal agents and fecal microbiota transplantation (FMT), and their implication in treating metabolic diseases are discussed. We highlight the unique role of gut mycobiome in metabolic diseases, providing perspectives for future research on gut mycobiome in metabolic diseases.

Keywords: Fungi; Mycobiome; NAFLD; Obesity; Type 2 diabetes.

Publication types

Review